Skip to main content
All inhalers

AIRDUO DIGIHALER

Fluticasone/Salmeterol

AIRDUO DIGIHALER

ICSLABA DPI

Fluticasone propionate / Salmeterol · Teva Pharmaceuticals

Clinical Reference

Active Medication & Mechanism

  • Fluticasone propionate ICS
    55 mcg or 113 mcg or 232 mcg per inhalation

    Synthetic corticosteroid with potent anti-inflammatory activity. Reduces airway inflammation by suppressing cytokines, chemokines, and inflammatory cell infiltration.

  • Salmeterol xinafoate LABA
    14 mcg per inhalation

    Long-acting beta2-adrenergic agonist producing sustained bronchodilation (≥12 hours) via smooth muscle relaxation.

FDA-Approved Dosing by Indication

// approval varies by strength + age
Asthma
3/4 approved regimens
  • 55/14 mcg FDA Approved
    Pop · Patients ≥12 years
    1 inhalation twice daily (~12 hours apart)
    For patients whose asthma is not adequately controlled on a low-dose ICS.
    Total · 110/28 mcg
  • 113/14 mcg FDA Approved
    Pop · Patients ≥12 years
    1 inhalation twice daily
    For patients not adequately controlled on medium-dose ICS.
    Total · 226/28 mcg
  • 232/14 mcg FDA Approved
    Pop · Patients ≥12 years
    1 inhalation twice daily
    For patients not adequately controlled on high-dose ICS.
    Total · 464/28 mcg
  • Any strength Not Approved
    Pop · Acute bronchospasm
    Total · Not a rescue inhaler. Use a SABA for acute symptoms.
Acute Use
0/1 approved regimens
  • Any strength Not Approved
    Pop · Acute bronchospasm / rescue
    Total · Not indicated for relief of acute bronchospasm. Use a SABA.

For clinical reference only. This workspace is intended for use by qualified healthcare professionals and is not a substitute for clinical judgement, prescribing information, or product monographs. Always verify doses and indications against the most current labelling before prescribing.

Inhaler Database · © inhalerdatabase.com 2024–2026 — All rights reserved